痹祺胶囊联合依托考昔治疗膝骨性关节炎的临床研究

Clinical study on Biqi Capsules combined with etoricoxib in treatment of knee osteoarthritis

目的探究痹祺胶囊联合依托考昔片治疗膝骨性关节炎的临床疗效。方法选取2015年2月—2017年10月天津市公安医院收治的膝骨性关节炎患者140例为研究对象,按随机数字表法将所有患者分为对照组和治疗组,每组各70例。对照组口服依托考昔片,1片/次,1次/d;治疗组在对照组基础上口服痹祺胶囊,4粒/次,3次/d。两组患者均治疗4周。观察两组的临床疗效,比较两组的视觉模拟评分法(VAS)评分、骨关节炎指数可视化量表(WOMAC)评分和健康调查简表(SF-36)评分,以及核因子κB(NF-κB)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、基质金属蛋白酶-3(MMP-3)、Ⅰ型胶原交联C-末端肽(CTX-Ⅰ)、Ⅱ型胶原C-末端肽(CTX-Ⅱ)、软骨寡聚基质蛋白(COMP)水平。结果治疗后,对照组和治疗组的总有效率分别为81.43%、92.86%,两组比较差异有统计学意义(P<0.05)。治疗后,两组VAS评分、WOMAC评分均明显降低,SF-36评分明显升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些评分明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清NF-κB、IL-1β、TNF-α水平均明显下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清CTX-Ⅰ、CTX-Ⅱ、COMP、MMP-3水平均明显下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些观察指标明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论痹祺胶囊联合依托考昔片治疗膝骨性关节炎具有较好的临床疗效,能改善临床症状,缓解炎症反应,提高关节活动功能,改善生活质量,具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Biqi Capsules combined with Etoricoxib Tablets in treatment of knee osteoarthritis. Methods Patients（140 cases） with knee osteoarthritis in Tianjin Public Security Hospital from February 2015 to October 2017 were randomly divided into control and treatment groups, and each group had 70 cases. Patients in the control group were po administered with Etoricoxib Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Biqi Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and VAS scores, WOMAC scores, SF-36 scores, and the levels of serum NF-κB, IL-1β, TNF-α, CTX-Ⅰ, CTX-Ⅱ, COMP, and MMP-3 in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.43% and 92.86%, respectively, and there was difference between two groups（P〈0.05）. After treatment, VAS scores and WOMAC scores in two groups were significantly decreased, but SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the levels of serum NF-κB, IL-1β and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the levels of serum CTX-Ⅰ, CTX-Ⅱ, COMP, and MMP-3 in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups（P〈0.05）. Conclusion Biqi Capsules combined with Etoricoxib Tablets has clinical curative effect in treatment of knee osteoarthritis, can improve clinical symptoms, alleviate inflammatory reaction, improve joint activity function, and improve quality of life, which has a certain clinical application value.